Breast cancer cells are more susceptible to the PARP inhibitor Olaparib, adriamycin, and cisplatin when YTHDF1 is knocked down, because it facilitates S-phase entrance, DNA replication, and DNA damage repair [43]. This evidence concerns the gene YTHDF1 and breast cancer.